Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Third degree AV block primary prevention
Introduction
Overview
Overview
Effective measurement for primary prevention of atrioventricular block due to dogoxine toxicity in patients with renal insufficiency is avoidance of dehydration, electrolytes imbalance and careful monitoring about heart block.
Primary prevention
Primary prevention
- Effective measurement for primary prevention of atrioventricular block due to dogoxin toxicity in patients with renal insufficiency is avoidance of dehydration, and electrolytes imbalance and careful monitoring about heart block.[1]
- In patients with renal insufficiency, potassium, electrolyte disturbances, and dehydration are predisposed to develop digoxin toxicity.
- Careful monitoring of electrolytes, drug levels, and renal function is essential in patients on chronic digoxin therapy.
- Patients on multiple AV nodal blocker agents (e.g., beta-blockers and calcium channel blockers) are at an increased risk for the development of atrioventricular (AV) block .
- These patients should be carefully monitored for heart blocks.
- Primary prevention of congenital complete heart block or second-degree AV block for women with SLE include taking hydroxychloroquine prior to conception.[2]
References
References
- ↑ Adamantidis MM, Duriez PR, Vincent AC, Dupuis BA (1983). “Digoxin-induced toxicity and experimental atrioventricular block in dogs. Relation between ventricular arrhythmias and oscillatory afterpotentials”. J Pharmacol. 14 (3): 333–49. PMID 6632915.
- ↑ Clowse MEB, Eudy AM, Kiernan E, Williams MR, Bermas B, Chakravarty E; et al. (2018). “The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices”. Rheumatology (Oxford). 57 (suppl_5): v9–v17. doi:10.1093/rheumatology/key141. PMC 6099126. PMID 30137589.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2]